LabConnect
has released its proprietary clinical trial sample tracking and management service, SampleGISTICS™.
Today’s clinical trials have increasingly complex analytical requirements that necessitate the utilization of multiple testing and biostorage facilities worldwide. This has led to gaps in sample visibility and downstream data management issues. “LabConnect developed this sample tracking service because of our clients’ need to locate their samples and data to effectively manage complex global clinical trials,” said Eric Hayashi, President and Chief Executive Officer. “Central laboratories have filled logistical and distribution gaps, but did not historically track the life cycle of samples, resulting in millions of dollars in unnecessary expenses, such as, lost samples, payroll costs, and time. LabConnect has the solution.”
The backbone of SampleGISTICS™ is LabConnect’s proprietary software, SampleREACH™, which provides Web-based, real-time sample tracking including collection, shipment, and receipt at any laboratory or location worldwide. In addition, the software enables instant accessioning, resulting in immediate identification and correction of queries including sample collection issues. SampleREACH™ provides detailed information about clients' samples including location, temperature, volume, freeze/thaw cycles, clinical data and has the ability to extract customizable reports. The tool’s forecast module makes budgeting more efficient and identifies when samples are missing.
As part of LabConnect’s complete laboratory services spanning a worldwide network of laboratories, SampleGISTICS™ eliminates the need to manually track samples by consolidating all of the information to one location. SampleGISTICS™ aims to significantly decreases the workload of site and clinical operations staff, allowing for faster decision making and a cost effective outcome.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.